Introduction
Activation of T-lymphocytes is a complex process requiring recognition of antigen by the T-cell antigen receptor as well as concomitant signals from the antigen-presenting cells. These events lead to the activation of second-messenger pathways such as tyrosine kinases and protein kinase C and to an increase in intracellular Ca2+ concentration [ 1-31. This initiates a sequential activation of a group of genes that in turn give rise to proliferation and immunological function [4, 5] . Cyclosporin A and FK506 are immunosuppressive drugs that have proved to be extremely powerful therapeutic agents both in the prevention of allograft rejection after solid organ engrafting and in the prophylactic treatment of graft/host disease after bone marrow transplantation [6-81. The immunosuppressive properties of cyclosporin A and FK506 can largely be ascribed to their potent inhibition of immunologically important cytokine genes during T-lymphocyte activation, including the interleukin (1L)-2, IL-3, IL-4, GMCSF and y-INF genes [9-121. Although structurally unrelated, both cyclosporin A and FK.506 inhibit lymphokine gene expression in a similar fashion.
Cyclosporin A binds and inhibits the activity of cyclophilin [ 131, a peptidyl-prolyl &-trans isomerase [14, 15] , an enzyme that plays a role in the folding of proteins in eiTto . Remarkably, FK506 also binds to a peptidyl-prolyl cistrans isomerase, FKBP (FK506 binding protein) [19, 20] , and inhibits its activity [21, 22] . This observation led initially to the hypothesis that peptidyl-prolyl cis-trans isomerases play a direct role in the T-cell transduction cascade. However, this was made less likely by the observations that cyclophilin and FKBP are extremely abundant, each accounting for approx. 0.5% of total cellular protein, but the concentration of drug required to inhibit T-cell activation completely is nevertheless significantly less than that required to saturate binding of the relevant receptor and hence inhibit cellular isomerase activity completely [23, 24] .
Abbreviations used: FKBP, FK506 binding protein; II,, interleukin.
Cyclosporin A and FK506 inhibit the activity of several transcription factors
Although the effects of cyclosporin A and FK506 on lymphokine genes seemed to be indistinguishable it was unclear whether their effects on signal transduction were similar. This was probed by studying their effect on the function of individual transcription factors [25, 26] . Tlymphocytes require the concordant actions of two signals derived from the antigen receptor and IL-1 or IL-6 for activation. These pathways can to some extent be mimicked by stimulation with a combination of a calcium ionophore and phorbol ester. Figure 1 illustrates the effects of cyclosporin A and FK506 on the activity of the transcription factor binding sites for N F I L U , NFILZB and NF-AT from the IL-2 gene, the NFKB binding site from the immunoglobulin light-chain gene and on the combined activity of both AP-I and SP-1 binding sites as stimulated by the combination of calcium ionophore and phorbol ester. The effects of the two drugs were similar on each of the four transcription factors that were inhibited and on each of the two transcription factors that were not inhibited. These dose-response relationships were consistent with previous reports that FK.506 is 100-fold more effective than cyclosporin A [27] . Inhibition of transcription by 50% was observed at concentrations of cyclosporin A and FK506 that are close to their binding constants to cyclophilin and FKBP, respectively, supporting the reports that suggest that cyclophilin and FKBP mediate the effects of cyclosporin A and FK.506 respectively [21, 22, 28] .
The observation that the effects of both cyclosporin A [25] and FK506 [26] were indistinguishable on the activity of several distinct transcription factors suggested that they inhibited a common target. In addition the strong correlation between a requirement for CaZ+ mobilization and sensitivity to cyclosporin A and FK506 suggested that these drugs interfere with the activity of a Caz+-regulated signalling pathway in Tlymphocytes [26, . The CaZt dependence of this signal transduction step is especially demonstrated by the effect of cyclosporin A and FK506 on the activity of transcription controlled by NFKB sites in T-lymphocytes. Transcription controlled by multiple copies of NFKB sites is inhibited when T-cells are stimulated by a Caz+ ionophore and PMA but not when T-cells are stimulated by PMA alone [26] . Although cyclosporin A and FK506 interfered with a Ca2+-dependent signalling pathway, not all signalling pathways regulated by increased intracellular Ca2+ concentration were inhibited by cyclosporin A or FK506. Cyclosporin A and FK506 had no effect on the level of Ca2+ ionophore-enhanced expression of c-fos mRNA [26] . These findings collectively suggested that cyclophilin and FKBP affect a novel signal-transduction step that requires an increase in intracellular Ca2+ concentration for the activation of several transcription factors involved in gene regulation during Tlymphocyte activation [26] .
Rapamycin competitively reverses the inhibition by FK506
Rapamycin, which is structurally related to FK506, does not inhibit T-cell activation induced by signals from the antigen receptor; on the contrary, it reverses the inhibition of FK506 on IL-2 production [32] and on the activity of all transcription factors inhibited by FK506 (P. Mattila and G. Crabtree, unpublished work). As shown in Figure 2 (a), a complete inhibition of NF-ATdriven transcription and transcription from the endogenous IL-2 gene is reversed by rapamycin. Stimulation of cells in the presence of a rapamycin by various concentrations of FK506 provided a dose-dependent shift of the FK506 dose-response curve in which a 10-fold change in the concentration of rapamycin produced a 10-fold decrease in the sensitivity to FK506 (Figure 2b ). At the 50% inhibition level, approx. 300-fold more rapamycin than FK506 was required to reverse the effect of FK506. Rapamycin, like FK506, binds to FKBP with a binding affinity similar to that of FK506, and it also inhibits the isomerase activity of FKBP [33] . These results do not favour the involvement of the isomerase activity in signal transduction in T-lymphocytes but can instead be explained by a model in which FK506 forms an inhibitory complex with FKBP that interferes with signal transduction of T-lymphocytes. A similar model, which includes a complex of a protein homologous to cyclophilin and cyclosporin A, has previously been demonstrated for cyclosporin A-mediated toxicity in Neurospora crassa and Saccharomyces cerevisiae [34] . This is supported by the finding that in N. crassa heterocaryons having one mutant allele of cyclophilin and one normal allelle die in the presence of cyclosporin A [34] . Furthermore all the cyclosporin A-resistant mutants either lack cyclophilin or have a mutation that prevents binding. This raised the possibility that similar inhibitory complexes of cyclophilin and cyclosporin A could mediate the effect of cyclosporin A in the activation of T-lymphocytes. Because cyclophilin and FKBP, collectively called immunophilins [23] , are proline isomerases and thus may be involved in the folding of several proteins, they may have an intrinsic characteristic of interacting with many different Volume 24 Transcription Factors as Third Messengers 
Identification of calcineurin as an essential step in signal transduction and as the target of drug-immunophilin complexes
T h e view that the complex of drug and immunophilin (the complex of cyclosporin A and cyclophilin, and the complex of FK506 and FKBP) per se directly interacted with a component of the signal transduction pathway and thereby inhibited signalling led to the search for cellular factors that bound specifically to drug-immunophilin complexes. This resulted in the identification of calcineurin, a serinehhreonine protein phosphatase, as the cellular target of both cyclosporin A-cyclophilin and FK506-FKBP complexes [35, 36] . Furthermore, it was shown that both drug-immunophilin complexes inhibited the activity of calcineurin towards a phosphopeptide substate in vitro. These studies were followed by a series of expression studies in vivo where overexpression of calcineurin in the T leukaemia cell line Jurkat resulted in a marked resistance of the inhibitory effects of cyclosporin A and FK506 137-391 and where expression of a constitutively active mutant of calcineurin was able to replace the normal requirement for calcium ionophore in the activation of transcription [38, 39] . Together, these results provided strong evidence for the notion that the inhibition of calcineurin's enzymic activity by drug-immunophilin complexes is the molecular basis of the action of cyclosporin A and FK506.
Concluding remarks
The studies with cyclosporin A and FK506 have provided valuable insights into the T-cell signaltransduction cascade and into the regulation of IL-2 gene expression; however, they have also
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revealed the remarkable sophistication of microbe evolution. Cyclosporin A, FK506 and rapamycin are all products of soil microbes that are beneficial for their hosts in that they are toxic to neighbouring microbes but non-toxic to their hosts. The requirement for a selective toxin is high specificity. The physicochemical correlate of biological specificity is a large surface area of interaction, necessitating a very large molecule. The microbes resolved this by producing a small molecule that binds to a bigger molecule, a peptidyl-prolyl cis-trans isomerase, which has an intrinsic characteristic of interacting with many different intracellular proteins by virtue of its function in the folding of polypeptide bonds. The formation of the toxin-isomerase complex resulted in a high specificity of interaction being lethal for the neighbour but harmless for the host. It remains to be seen whether other so far unidentified drug-isomerase complexes will be found and whether they will reveal undiscovered steps in signal transduction pathways. 
Introduction
Yeast cells become committed to enter and complete the mitotic cell cycle at a point known as Start in late G1. At Start a transcriptional programme is initiated, involving at least two transcription factors, SBF and DSCUMBF (for a review see [1, 2] 
A novel transcription factor activating MCB and SCB elements
A reporter plasmid consisting of three MCB elements upstream of the cytochrome c minimal promoter and the Escherichia coli lacZ gene [6] was introduced into a swi6A strain. The swi6 mutation reduced expression from the reporter [lo], allowing us to isolate a gene from a highcopy-number genomic library able to stimulate lacZ expression [ 131. The gene identified, BRYl (see below), was interacting directly with the MCB elements as their mutation abolished BRYl -induced expression. BRYl was not, however, specific for MCB elements as it also stimulated expression from the same reporter construct containing SCB instead of MCB elements.
DNA sequencing revealed BRYl to be identical with a recently identified gene, SKhT7, isolated as a suppressor of a cell-wall defect in budding yeast [14] . The most striking feature of the protein is the presence of a receiver domain (Figure l ) , previously only found in the response-regulator proteins from bacterial twocomponent signal transduction systems (for reviews see [ 15-171 ). The response-regulator is usually the transcription factor, the effector, of 
